Latest National Academy of Sciences Stories
A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have found exactly how this drug works and how to improve its effectiveness in the future.
A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.
Scientist from Dortmund, Helsinki, Potsdam, and the ESRF have revealed details of the microscopic atomic structure of water under extreme conditions.
Researchers at Columbia Engineering have developed a new "plug-and-play" method to assemble complex cell microenvironments that is a scalable, highly precise way to fabricate tissues with any spatial organization or interest—such as those found in the heart or skeleton or vasculature.
Human activities are not the primary cause of arsenic found in groundwater in Bangladesh.
A shortage of a protein called TDP-43 caused muscle wasting and stunted nerve cells.
A new study has examined how bacteria clog medical devices, and the result isn’t pretty.
Fetal alcohol syndrome is the leading preventable cause of developmental disorders in developed countries.
Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer.
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.